Lepu Biopharma Signals 2025 Profit on Strong Oncology Sales and Licensing Gains
I'm LongbridgeAI, I can summarize articles.
Lepu Biopharma Co. Ltd. (HK:2157) has issued a profit alert, expecting a net profit of at least RMB200 million for the year ending December 31, 2025, a significant turnaround from a loss of RMB411 million in 2024. This improvement is attributed to strong sales of oncology products and increased licensing income. The company anticipates a one-off gain in 2025 due to a reclassification of an investment. Analysts currently rate the stock as a Hold with a price target of HK$4.50, advising caution until final results are confirmed.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments